156 related articles for article (PubMed ID: 9118041)
1. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
Wadler S; Schwartz EL; Haynes H; Rameau R; Quish A; Mandeli J; Gallagher R; Hallam S; Fields A; Goldberg G; McGill F; Jennings S; Wallach RC; Runowicz CD
Cancer; 1997 Apr; 79(8):1574-80. PubMed ID: 9118041
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
Adamson PC; Reaman G; Finklestein JZ; Feusner J; Berg SL; Blaney SM; O'Brien M; Murphy RF; Balis FM
J Clin Oncol; 1997 Nov; 15(11):3330-7. PubMed ID: 9363862
[TBL] [Abstract][Full Text] [Related]
3. Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials.
Braud AC; Gonzague L; Bertucci F; Genre D; Camerlo J; Gravis G; Goncalves A; Moutardier V; Viret F; Maraninchi D; Viens P
Eur Cytokine Netw; 2002; 13(1):115-20. PubMed ID: 11956030
[TBL] [Abstract][Full Text] [Related]
4. Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.
Wadler S; Schwartz EL; Anderson P; Runowicz CD; Chuang L; Del Priore G; Hochster H; Goldberg G; Fields A; Loewen G; Haynes H
Cancer J Sci Am; 1999; 5(3):165-70. PubMed ID: 10367173
[TBL] [Abstract][Full Text] [Related]
5. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
Weiss GR; Liu PY; Alberts DS; Peng YM; Fisher E; Xu MJ; Scudder SA; Baker LH; Moore DF; Lippman SM
Gynecol Oncol; 1998 Dec; 71(3):386-90. PubMed ID: 9887236
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics.
Goncalves A; Camerlo J; Bun H; Gravis G; Genre D; Bertucci F; Resbeut M; Pech-Gourg F; Durand A; Maraninchi D; Viens P
Anticancer Res; 2001; 21(2B):1431-7. PubMed ID: 11396227
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
Skeel RT; Huang J; Manola J; Wilding G; Dreicer R; Walker P; Muggia F; Crawford ED; Dutcher JP; Loehrer PJ
Cancer Invest; 2003; 21(1):41-6. PubMed ID: 12643008
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
Boorjian SA; Milowsky MI; Kaplan J; Albert M; Cobham MV; Coll DM; Mongan NP; Shelton G; Petrylak D; Gudas LJ; Nanus DM
J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
[TBL] [Abstract][Full Text] [Related]
9. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M
Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of all-trans-retinoic acid and alpha-interferon in patients with advanced non-small cell lung cancer.
Athanasiadis I; Kies MS; Miller M; Ganzenko N; Joob A; Marymont M; Rademaker A; Gradishar WJ
Clin Cancer Res; 1995 Sep; 1(9):973-9. PubMed ID: 9816069
[TBL] [Abstract][Full Text] [Related]
11. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
[TBL] [Abstract][Full Text] [Related]
12. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon.
Dunst J; Hänsgen G; Lautenschläger C; Füchsel G; Becker A
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):367-73. PubMed ID: 10030263
[TBL] [Abstract][Full Text] [Related]
13. [13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva].
Römisch M; Meier W; Kimmig R; Hepp H
Geburtshilfe Frauenheilkd; 1996 Oct; 56(10):520-4. PubMed ID: 9036064
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.
Enzinger PC; Ilson DH; Saltz LB; Martin LK; Kelsen DP
Cancer; 1999 Mar; 85(6):1213-7. PubMed ID: 10189124
[TBL] [Abstract][Full Text] [Related]
15. An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92.
Schiller JH; Neuberg D; Burns D; Ritch P; Larson M; Levitt M; Dutcher J
Invest New Drugs; 1997; 15(4):319-24. PubMed ID: 9547674
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
Goldberg JS; Vargas M; Rosmarin AS; Milowsky MI; Papanicoloau N; Gudas LJ; Shelton G; Feit K; Petrylak D; Nanus DM
Cancer; 2002 Sep; 95(6):1220-7. PubMed ID: 12216088
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
18. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
19. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Holdener E; Krakoff IH
J Natl Cancer Inst; 1992 Feb; 84(4):241-5. PubMed ID: 1734085
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
